Skip to main content
SpringerLink
Log in

Melanoma Cell Autonomous Growth: The Rb/E2F Pathway

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Abstract

Transformation of normal melanocytes to metastatic melanoma cells is characterized by loss of dependency on external growth factors required for the viability and proliferation of normal melanocytes. The molecular events that lead to melanoma cell autonomous growth are not well defined, but are likely to include sustained activity of cyclin-dependent kinases (CDK2, CDK4 and CDK6) as a result of loss of CDK inhibitors (such as p16INK4a and possibly p27KIP1), and persistent upregulation of several cyclins (cyclin D1, cyclin A and cyclin E), the positive regulators of CDKs. CDKs phosphorylate, and consequently, inactivate the retinoblastoma family of tumor suppressor proteins (pRb, p107 and p130), termed pocket proteins. The inactivation of pocket proteins liberates E2F transcription factors from suppressive complexes ('free' E2F) that, in turn, induces the continuous expression of target genes whose products promote cell cycle progression. In normal melanocytes, external growth factors suppress the activity of all three pocket proteins, allowing E2F activity to accumulate and sustain transcription of target genes required for cell proliferation. In contrast, in melanoma cells from advanced lesions, all three pocket proteins are highly phosphorylated and inactive, even in the absence of environmental mitogens, and free E2F activity is constitutively high. Manipulations of normal mouse melanocytes in vitro, and in vivo in transgenic mouse expressing ectopic genes, further support the notion that growth rate, and release from dependency on external mitogens, positively correlate with inactivation of pocket proteins. The latter has been accomplished by sustained cell surface receptor stimulation, such as constitutive high expression of a growth factor, or by sequestration with dominantly acting viral proteins. Taken together, chronic hyperphosphorlyation/inactivation of pRb, p107 and p130 is probably one of the key events in converting growth-factor dependent normal melanocytes, to autonomously growing melanoma cells. Since all pocket proteins are regulated by CDKs activity, it is likely that agents that inhibit this class of enzymes will be effective in treating melanoma patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pawson T, Hunter T: Signal transduction and growth control in normal and cancer cells (editorial) (Review). Curr Opin Genet Dev 4: 1-4, 1994

    Google Scholar 

  2. Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996

    Google Scholar 

  3. Porter AC, Vaillancourt RR: Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene 17: 1343-1352, 1998

    Google Scholar 

  4. Böhm M, Moellmann G, Cheng E, Alvarez-Franco M, Wagner S, Sassone-Corsi P, Halaban R: Identification of p90RSK as the probable CREB-Ser133 kinase in human melanocytes. Cell Growth Differ 6: 291-302, 1995

    Google Scholar 

  5. Halaban R: Growth regulation in normal and malignant melanocytes. In: Hecker E, Marks F, Jung EG, Tilgen W (eds), Recent Results in Cancer Research, Vol 128, Springer-Verlag, Berlin-Heidelberg, 1993, pp 133-149

    Google Scholar 

  6. Halaban R, Rubin JS, Funasaka Y, Cobb M, Boulton T, Faletto D, Rosen E, Chan A, YoKo K, White W, Cook C, Moellmann G: Met and hepatocyte growth factor/scatter factor signal transduction in normal melanocytes and melanoma cells. Oncogene 7: 2195-2206, 1992

    Google Scholar 

  7. Funasaka Y, Boulton T, Cobb M, Yarden Y, Fan B, Lyman SD, Williams DE, Anderson DM, Zakut R, Mishima Y, Halaban R: c-Kit kinase induces a cascade of protein tyrosine-phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is down regulated in melanomas. Mol Biol Cell 3: 197-209, 1992

    Google Scholar 

  8. Imokawa G, Yada Y, Miyagishi M: Endothelins secreted from human keratinocytes are intrinsic mitogens for human melanocytes. J Biol Chem 267: 24675-24680, 1992

    Google Scholar 

  9. Abdel-Malek Z, Swope VB, Suzuki I, Akcali C, Harriger MD, Boyce ST, Urabe K, Hearing VJ: Mitogenic and melanogenic stimulation of normal human melanocytes by melanotropic peptides. Proc Natl Acad Sci USA 92: 1789-1793, 1995

    Google Scholar 

  10. Hunt G, Todd C, Cresswell JE, Thody AJ: Alpha-melanocyte stimulating hormone and its analogue Nle4DPhe7 alpha-MSH affect morphology, tyrosinase activity and melanogenesis in cultured human melanocytes. J Cell Sci 107: 205-211, 1994

    Google Scholar 

  11. Suzuki I, Cone RD, Im S, Nordlund J, Abdel-Malek ZA: Binding of melanotropic hormones to the melanocortin receptor MC1R on human melanocytes stimulates proliferation and melanogenesis. Endocrinology 137: 1627-1633, 1996

    Google Scholar 

  12. Swope VB, Medrano EE, Smalara D, Abdel-Malek ZA: Long-term proliferation of human melanocytes is supported by the physiologic mitogens alpha-melanotropin, endothelin-1, and basic fibroblast growth factor. Exp Cell Res 217: 453-459, 1995

    Google Scholar 

  13. Matsumoto K, Tajima H, Nakamura T: Hepatocyte growth factor is a potent stimulator of human melanocyte DNA synthesis and growth. Biochem Biophys Res Commun 176: 45-51, 1991

    Google Scholar 

  14. Halaban R: Growth factors and melanomas (Review). Sem Oncol 23: 673-681, 1996

    Google Scholar 

  15. Bull HA, Bunker CB, Terenghi G, Springall DR, Zhao Y, Polak JM, Dowd PM: Endothelin-1 in human skin: immunolocalization, receptor binding, mRNA expression, and effects on cutaneous microvascular endothelial cells. J Invest Dermatol 97: 618-623, 1991

    Google Scholar 

  16. Hara M, Yaar M, Gilchrest BA: Endothelin-1 of keratinocyte origin is a mediator of melanocyte dendricity. J Invest Dermatol 105: 744-748, 1995

    Google Scholar 

  17. Halaban R, Tyrrell L, Longley J, Yarden Y, Rubin J: Pigmentation and proliferation of human melanocytes and the effects of melanocyte-stimulating hormone and ultraviolet B light. Ann NY Acad Sci 680: 290-301, 1993

    Google Scholar 

  18. Tada A, Suzuki I, Im S, Davis MB, Cornelius J, Babcock G, Nordlund JJ, Abdel-Malek ZA: Endothelin-1 is a paracrine growth factor that modulates melanogenesis of human melanocytes and participates in their responses to ultraviolet radiation. Cell Growth Differ 9: 575-584, 1998

    Google Scholar 

  19. Pawelek JM, Chakraborty AK, Osber MP, Orlow SJ, Min KK, Rosenzweig KE, Bolognia JL: Molecular cascases in UV-induced melanogenesis: a central role for melanotropins? (Review). Pigm Cell Res 5: 348-356, 1992

    Google Scholar 

  20. Bhardwaj RS, Luger TA: Proopiomelanocortin production by epidermal cells: evidence for an immune neuroendocrine network in the epidermis (Review). Arch Dermatol Res 287: 85-90, 1994

    Google Scholar 

  21. Luger TA, Scholzen T, Brzoska T, Becher E, Slominski A, Paus R: Cutaneous immunomodulation and coordination of skin stress responses by alpha-melanocyte-stimulating hormone. Ann NY Acad Sci 840: 381-394, 1998

    Google Scholar 

  22. Luger TA: Immunomodulation by UV light: role of neuropeptides. Eur J Dermatol 8: 198-199, 1998

    Google Scholar 

  23. Costa JJ, Demetri GD, Harrist TJ, Dvorak AM, Hayes DF, Merica EA, Menchaca DM, Gringeri AJ, Schwartz LB, Galli SJ: Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med 183: 2681-2686, 1996

    Google Scholar 

  24. Grichnik JM, Burch JA, Burchette J, Shea CR: The SCF/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis. J Invest Dermatol 111: 233-238, 1998

    Google Scholar 

  25. Lerner AB, McGuire J: Effect of α-and β-melanocyte-stimulating hormones on the skin colour of man. Nature 189: 176-179, 1961

    Google Scholar 

  26. Hadley ME, Sharma SD, Hruby VJ, Levine N, Dorr RT: Melanotropic peptides for therapeutic and cosmetic tanning of the skin (Review). Ann NY Acad Sci 680:424-439, 1993

    Google Scholar 

  27. Hadley ME, Hruby VJ, Blanchard J, Dorr RT, Levine N, Dawson BV, al-Obeidi F, Sawyer TK: Discovery and development of novel melanogenic drugs. Melanotan-I and-II. Pharm Biotechnol 11: 575-595, 1998

    Google Scholar 

  28. Halaban R, Moellmann G: White mutants in mice shedding light on humans. J Invest Dermatol 100(Suppl): 176s-185s, 1993

    Google Scholar 

  29. Spritz RA: Molecular basis of human piebaldism (Review). J Invest Dermatol 103: 137S-140S, 1994

    Google Scholar 

  30. Puffenberger EG, Hosoda K, Washington SS, Nakao K, Dewit D, Yanagisawa M, Chakravarti A: A missense mutation of the endothelin-B receptor gene in multigenic Hirschsprung's disease. Cell 79: 1257-1266, 1994

    Google Scholar 

  31. Artie T, Till M, Pelet A, Amiel J, Edery P, Boutrand L, Munnich A, Lyonnet S: Mutation of the endothelin-receptor B gene in Waardenburg-Hirschsprung disease. Hum Mol Genet 4: 2407-2409, 1995

    Google Scholar 

  32. Edery P, Attie T, Amiel J, Pelet A, Eng C, Hofstra RM, Martelli H, Bidaud C, Munnich A, Lyonnet S: Mutation of the endothelin-3 gene in the Waardenburg-Hirschsprung disease (Shah-Waardenburg syndrome). Nat Genet 12: 442-444, 1996

    Google Scholar 

  33. Amiel J, Attie T, Jan D, Pelet A, Edery P, Bidaud C, Lacombe D, Tam P, Simeoni J, Flori E, Nihoul-Fekete C, Munnich A, Lyonnet S: Heterozygous endothelin receptor B (EDNRB) mutations in isolated Hirschsprung disease. Hum Mol Genet 5: 355-357, 1996

    Google Scholar 

  34. Seri M, Yin L, Barone V, Bolino A, Celli I, Bocciardi R, Pasini B, Ceccherini I, Lerone M, Kristoffersson U, Larsson LT, Casasa JM, Cass DT, Abramowicz MJ, Vanderwinden JM, Kravcenkiene I, Baric I, Silengo M, Martucciello G, Romeo G: Frequency of RET mutations in long-and short-segment Hirschsprung disease. Hum Mutat 9: 243-249, 1997

    Google Scholar 

  35. Hofstra RM, Osinga J, Tan-Sindhunata G, Wu Y, Kamsteeg EJ, Stulp RP, van Ravenswaaij-Arts C, Majoor-Krakauer D, Angrist M, Chakravarti A, Meijers C, Buys CH: A homozygous mutation in the endothelin-3 gene associated with a combined Waardenburg type 2 and Hirschsprung phenotype (Shah-Waardenburg syndrome). Nat Genet 12: 445-447, 1996

    Google Scholar 

  36. Fleischman RA: From white spots to stem cells: the role of the Kit receptor in mammalian development (Review). Trends Genet 9: 285-290, 1993

    Google Scholar 

  37. Baynash AG, Hosoda K, Giaid A, Richardson JA, Emoto N, Hammer RE, Yanagisawa M: Interaction of endothelin-3 with endothelin-B receptor is essential for development of epidermal melanocytes and enteric neurons. Cell 79: 1277-1285, 1994

    Google Scholar 

  38. Hosoda K, Hammer RE, Richardson JA, Baynash AG, Cheung JC, Giaid A, Yanagisawa M: Targeted and natural (piebald-lethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice. Cell 79: 1267-1276, 1994

    Google Scholar 

  39. Pawson T: Protein modules and signalling networks. Nature 373: 573-580, 1995

    Google Scholar 

  40. Adams PD, Kaelin WG, Jr: Transcriptional Control by E2F (Review). Semin Cancer Biol 6: 99-108, 1995

    Google Scholar 

  41. Adams PD, Kaelin WG, Jr: The cellular effects of E2F over-expression (Review). Curr Top Microbiol Immunol 208: 79-93, 1996

    Google Scholar 

  42. Sherr CJ: Growth factor-regulated Gl cyclins (Review). Stem Cells 1: 47-55, 1994

    Google Scholar 

  43. Sherr CJ: G1 phase progression: cycling on cue (see comments) (Review). Cell 79: 551-555, 1994

    Google Scholar 

  44. Weinberg RA: The retinoblastoma protein and cell cycle control (Review). Cell 81: 323-330, 1995

    Google Scholar 

  45. Kaelin WG, Jr: Recent insights into the functions of the retinoblastoma susceptibility gene product (Review) (183 refs.). Cancer Invest 15: 243-254, 1997

    Google Scholar 

  46. Sherr CJ: Mammalian G1 cyclins and cell cycle progression (Review). Proc Assoc Am Physicians 107: 181-186, 1995

    Google Scholar 

  47. Zarkowska T, Mittnacht S: Differential phosphorylation of the retinoblastoma protein by G1/S cyclin-dependent kinases. J Biol Chem 272: 12738-12746, 1997

    Google Scholar 

  48. Weinberg RA: The molecular basis of carcinogenesis — understanding the cell cycle clock. Cytokines Mol Ther 2: 105-110, 1996

    Google Scholar 

  49. Taya Y: Rb kinases and Rb-binding proteins: new points of view (Review). Trends Biochem Sci 22: 14-17, 1997

    Google Scholar 

  50. Pardee A: G1 events and regulation of cell proliferation. Science 246: 603-608, 1989

    Google Scholar 

  51. Bartek J, Bartkova J, Lukas J: The retinoblastoma protein pathway and the restriction point. Curr Opin Cell Biol 8: 805-814, 1996

    Google Scholar 

  52. Planas-Silva MD, Weinberg RA: The restriction point and control of cell proliferation (Review article). Curr Opin Cell Biol 9: 768-772, 1997

    Google Scholar 

  53. Nevins JR: Toward an understanding of the functional complexity of the E2F and retinoblastoma families (Review) (100 refs.). Cell Growth Differ 9: 585-593, 1998

    Google Scholar 

  54. Jacks T, Weinberg RA: Cell-cycle control and its watchman. Nature 381: 643-644, 1996

    Google Scholar 

  55. Weinberg RA: How cancer arises (Review) (0 refs.). Sci Am 275: 62-70, 1996

    Google Scholar 

  56. Grana X, Garriga J, Mayol X: Role of the retinoblastoma protein family, pRB, p107 and p130 in the negative control of cell growth. Oncogene 17: 3365-3383, 1998

    Google Scholar 

  57. Johnson DG, Schneider-Broussard R: Role of E2F in cell cycle control and cancer. Front Biosci 27: d447-d448, 1998

    Google Scholar 

  58. Hiyama H, Iavarone A, Reeves SA: Regulation of the CDK inhibitor p21 gene during cell cycle progression is under the control of the transcription factor E2F. Oncogene 16: 1513-1523, 1998

    Google Scholar 

  59. Kos L, Aronzon A, Takayama H, Maina F, Ponzetto C, Merlino G, Pavan W: Hepatocyte growth factor/scatter factor-MET signaling in neural crest-derived melanocyte development. Pigm Cell Res 12: 13-21, 1999

    Google Scholar 

  60. Otsuka T, Takayama H, Sharp R, Celli G, LaRochelle WJ, Bottaro DP, Ellmore N, Vieira W, Owens JW, Anver M, Merlino G: c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype. Cancer Res 58: 5157-5167, 1998

    Google Scholar 

  61. Kato M, Takahashi M, Akhand AA, Liu W, Dai Y, Shimizu S, Iwamoto T, Suzuki H, Nakashima I: Transgenic mouse model for skin malignant melanoma. Oncogene 17: 1885-1888, 1998

    Google Scholar 

  62. Anders F: Tumour formation in platyfish-swordtail hybrids as a problem of gene regulation. Experientia 23: 1-10, 1967

    Google Scholar 

  63. Schartl A, Malitschek B, Kazianis S, Borowsky R, Schartl M: Spontaneous melanoma formation in nonhybrid Xiphophorus. Cancer Res 55: 159-165, 1995

    Google Scholar 

  64. Wellbrock C, Fischer P, Schartl M: Receptor tyrosine kinase Xmrk mediates proliferation in Xiphophorus melanoma cells. Int J Cancer 76: 437-442, 1998

    Google Scholar 

  65. Wellbrock C, Geissinger E, Gomez A, Fischer P, Friedrich K, Schartl M: Signalling by the oncogenic receptor tyrosine kinase Xmrk leads to activation of STAT5 in Xiphophorus melanoma. Oncogene 16: 3047-3056, 1998

    Google Scholar 

  66. Powell MB, Hyman P, Bell OD, Balmain A, Brown K, Alberts D, Bowden GT: Hyperpigmentation and melanocytic hyperplasia in transgenic mice expressing the human T24 Ha-ras gene regulated by a mouse tyrosinase promoter. Molec Carcinogen 12: 82-90, 1995

    Google Scholar 

  67. Chin L, Pomerantz J, Polsky D, Jacobson M, Cohen C, Cordon-Cardo C, Horner II JW, DePinho RA: Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev 11: 2822-2834, 1997

    Google Scholar 

  68. Chin L, Pomerantz J, Wwong M, Holash J, Bardeesy N, Shen Q, O'hagan R, Pantginis J, Zhou H, Horner II JW, Cordon-Cardo C, Yancopoulos GD, DePinho RA: Essential role for oncogenic Ras in tumour maintenance. Nature 400: 468-472, 1999

    Google Scholar 

  69. Sherr CJ: Mammalian G1 cyclins (Review). Cell 73: 1059-1065, 1993

    Google Scholar 

  70. Kerhoff E, Rapp UR: Cell cycle targets of Ras/Raf signalling. Oncogene 17: 1457-1462, 1998

    Google Scholar 

  71. Larue L, Dougherty N, Mintz B: Genetic predisposition of transgenic mouse melanocytes to melanoma results in malignant melanoma after exposure to a low ultraviolet B intensity nontumorigenic for normal melanocytes. Proc Natl Acad Sci USA 89: 9534-9538, 1992

    Google Scholar 

  72. Mintz B, Silvers WK: Transgenic mouse model of malignant skin melanoma. Proc Natl Acad Sci USA 90: 8817-8821, 1993

    Google Scholar 

  73. Klein-Szanto AJ, Silvers WK, Mintz B: Ultraviolet radiation-induced malignant skin melanoma in melanoma-susceptible transgenic mice. Cancer Res 54: 4560-4572, 1994

    Google Scholar 

  74. Kelsall SR, Mintz B: Metastatic cutaneous melanoma promoted by ultraviolet radiation in mice with transgene-initiated low melanoma susceptibility. Cancer Res 58: 4061-4065, 1998

    Google Scholar 

  75. Wilson RE, Dooley TP, Hart IR: Induction of tumorigenicity and lack of in vitro growth requirement for 12-O-tetradecancoylphorbol-13-acetate by transfection of murine melanocytes with v-Ha-ras. Cancer Res 49: 711-716, 1989

    Google Scholar 

  76. Dotto GP, Moellmann G, Ghosh S, Edwards M, Halaban R: Transformation of murine melanocytes by basic fibroblast growth factor cDNA and oncogenes and selective suppression of the transformed phenotype in a reconstituted cutaneous environment. J Cell Biol 109: 3115-3128, 1989

    Google Scholar 

  77. Ramon Y, Cajal S, Suster S, Halaban R, Filvaroff E, Dotto GP: Induction of different morphologic features of malignant melanoma and pigmented lesions after transformation of murine melanocytes with bFGF-cDNA and H-ras, myc, neu, and E1a oncogenes. Am J Pathol 138: 349-358, 1991

    Google Scholar 

  78. Halaban R, Böhm M, Dotto P, Moellmann G, Cheng E, Zhang YH: Growth regulatory proteins that repress differentiation markers in melanocytes also downregulate the transcription factor Microphthalmia. J Invest Dermatol 106: 1266-1272, 1996

    Google Scholar 

  79. Dooley TP, Wilson RE, Jones NC, Hart IR: Polyoma middle T abrogates TPA requirement of murine melanocytes and induces malignant melanoma. Oncogene 3: 531-535, 1988

    Google Scholar 

  80. Albino AP, Sozzi G, Nanus DM, Jhanwar SC, Houghton AN: Malignant transformation of human melanocytes: induction of a complete melanoma phenotype and genotype. Oncogene 7: 2315-2321, 1992

    Google Scholar 

  81. Jambrosic J, Mancianti ML, Ricciardi R, Sela BA, Koprowski H, Herlyn M: Transformation of normal human melanocytes and non-malignant nevus cells by adenovirus 12-SV40 hybrid virus. Int J Cancer 44: 1117-1123, 1989

    Google Scholar 

  82. Herlyn M, Satyamoorthy K: Activated ras. Yet another player in melanoma? (comment) (Review). Am J Pathol 149: 739-744, 1996

    Google Scholar 

  83. Edery P, Eng C, Munnich A, Lyonnet S: RET in human development and oncogenesis. Bioessays 19: 389-395, 1997

    Google Scholar 

  84. Natali PG, Nicotra MR, Di Renzo MF, Prat M, Bigotti A, Cavaliere R, Comoglio PM: Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression. Br J Cancer 68: 746-750, 1993

    Google Scholar 

  85. Halaban R, Rubin W, White W: Met and HGF/SF in normal melanocytes and melanoma cells. In: Goldberg ID (ed) Hepatocyte Growth Factor-Scatter Factor and the c-Met Receptor, Birkhäuser Verlag, Basel, Switzerland, 1993, pp 329-339

    Google Scholar 

  86. Kraehn GM, Schartl M, Peter RU: Human malignant melanoma-a genetic disease. Cancer 75: 1228-1237, 1995

    Google Scholar 

  87. Natali PG, Nicotra MR, Digiesi G, Cavaliere R, Bigotti A, Trizio D, Segatto O: Expression of gp185HER-2 in human cutaneous melanoma: implications for experimental immunotherapeutics. Int J Cancer 56: 341-346, 1994

    Google Scholar 

  88. Luan J, Shattuck-Brandt R, Haghnegahdar H, Owen JD, Strieter R, Burdick M, Nirodi C, Beauchamp D, Johnson KN, Richmond A: Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression. J Leukoc Biol 62: 588-597, 1997

    Google Scholar 

  89. Rodeck U, Herlyn M: Growth factors in melanoma (Review). Cancer Metastasis Rev 10: 89-101, 1991

    Google Scholar 

  90. Richmond A: The pathogenic role of growth factors in melanoma (Review). Semin Dermatol 10: 246-255, 1991

    Google Scholar 

  91. Richmond A, Thomas HG: Purification of melanoma growth stimulatory activity. J Cell Physiol 129: 375-384, 1986

    Google Scholar 

  92. Bordoni R, Fine R, Murray D, Richmond A: Characterization of the role of melanoma growth stimulatory activity (MGSA) in the growth of normal melanocytes, nevocytes, and malignant melanocytes. J Cell Biochem 44: 207-219, 1990

    Google Scholar 

  93. Balentien E, Mufson BE, Shattuck RL, Derynck R, Richmond A: Effects of MGSA/GRO alpha on melanocyte transformation. Oncogene 6: 1115-1124, 1991

    Google Scholar 

  94. Rodeck R, Melber K, Kath R, Menssen H-D, Varello M, Atkinson B, Herlyn M: Constitutive expression of multiple growth factor genes by melanoma cells but not normal melanocytes. J Invest Dermatol 97: 20-26, 1991

    Google Scholar 

  95. Rodeck U, Becker D, Herlyn M: Basic fibroblast growth factor in human melanoma (Review). Cancer Cells 3: 308-311, 1991

    Google Scholar 

  96. Albino AP: The role of oncogenes and growth factors in progressive melanomagenesis (Review). Pigm Cell Res 2: 199-218, 1992

    Google Scholar 

  97. Scott G, Stoler M, Sarkar S, Halaban R: Localization of basic fibroblast growth factor mRNA in melanocytic lesions by in situ hybridization. J Invest Dermatol 96: 318-322, 1991

    Google Scholar 

  98. Ueda M, Funasaka Y, Ichihashi M, Mishima Y: Stable and strong expression of basic fibroblast growth factor in naevus cell naevus contrasts with aberrant expression in melanoma. Br J Dermatol 130: 320-324, 1994

    Google Scholar 

  99. al-Alousi S, Carlson JA, Blessing K, Cook M, Karaoli T, Barnhill RL: Expression of basic fibroblast growth factor in desmoplastic melanoma. J Cutan Pathol 23: 118-125, 1996

    Google Scholar 

  100. Reed JA, McNutt NS, Albino AP: Differential expression of basic fibroblast growth factor (bFGF) in melanocytic lesions demonstrated by in situ hybridization. Implications for tumor progression. Am J Pathol 144: 329-336, 1994

    Google Scholar 

  101. Xerri L, Battyani Z, Grob JJ, Parc P, Hassoun J, Bonerandi JJ, Birnbaum D: Expression of FGF1 and FGFR1 in human melanoma tissues. Melanoma Res 6: 223-230, 1996

    Google Scholar 

  102. Yayon A, Ma YS, Safran M, Klagsbrun M, Halaban R: Suppression of autrocrine cell proliferation and tumorigenesis of human melanoma cells and fibroblast growth factor transformed fibroblasts by a kinase-deficient FGF receptor 1: evidence for the involvement of Src-family kinases. Oncogene 14: 2999-3009, 1997

    Google Scholar 

  103. Wang Y, Becker D: Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nature Med 3: 887-893, 1997

    Google Scholar 

  104. Dyson N, Bernards R, Friend SH, Gooding LR, Hassell JA, Major EO, Pipas JM, Vandyke T, Harlow E: Large T antigens of many polyomaviruses are able to form complexes with the retinoblastoma protein. J Virol 64: 1353-1356, 1990

    Google Scholar 

  105. Stubdal H, Zalvide J, DeCaprio JA: Simian virus 40 large T antigen alters the phosphorylation state of the Rb-related proteins p130 and p107. J Virol 70: 2781-2788, 1996

    Google Scholar 

  106. Stubdal H, Zalvide J, Campbell KS, Schweitzer C, Roberts TM, DeCaprio JA: Inactivation of pRB-related proteins p130 and p107 mediated by the J domain of simian virus 40 large T antigen. Mol Cell Biol 17: 4979-4990, 1997

    Google Scholar 

  107. Zalvide J, Stubdal H, DeCaprio JA: The J domain of simian virus 40 large T antigen is required to functionally inactivate RB family proteins. Mol Cell Biol 18: 1408-1415, 1998

    Google Scholar 

  108. Ranade K, Hussussian CJ, Sikorski RS, Varmus HE, Goldstein AM, Tucker MA, Serrano M, Hannot GJ, Beach D, Dracopoli NC: Mutations associated with familial melanoma impair p16INK4 function (letter). Nat Genet 10: 114-116, 1995

    Google Scholar 

  109. Liu L, Lassam NJ, Slingerland JM, Bailey D, Cole D, Jenkins R, Hogg D: Germline p16INK4a mutation and protein dysfunction in a family with inherited melanoma. Oncogene 11: 405-412, 1995

    Google Scholar 

  110. Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, Hayward N, Dracopoli NC: Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12: 97-99, 1996

    Google Scholar 

  111. Walker GJ, Hussussian CJ, Flores JF, Glendening JM, Haluska FG, Dracopoli NC, Hayward NK, Fountain JW: Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum Mol Genet 4: 1845-1852, 1995

    Google Scholar 

  112. Haluska FG, Housman DE: Recent advances in the molecular genetics of malignant melanoma. Cancer Surv 25: 277-292, 1995

    Google Scholar 

  113. Cannon-Albright LA, Kamb A, Skolnick M: A review of inherited predisposition to melanoma. (Review)(66 refs.). Semin Oncol 23: 667-672, 1996

    Google Scholar 

  114. Kamb A: Cyclin-dependent kinase inhibitors and human cancer (Review) (44 refs.). Curr Topics Microbiol Immunol 227: 139-148, 1998

    Google Scholar 

  115. Bartkova J, Lukas J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J, Bartek J: The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 56: 5475-5483, 1996

    Google Scholar 

  116. Halaban R, Miglarese MR, Smicun Y, Puig S: Melanomas, from the cell cycle point of view (Review). Int J Mol Med 1: 419-425, 1998

    Google Scholar 

  117. Horowitz JM, Park S-H, Bogenman E, Cheng J-C, Yandell DW, Kaye FJ, Minna JD, Dryja TP, Weinberg RA: Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci USA 87: 2772-2779, 1990

    Google Scholar 

  118. Bataille V, Hiles R, Bishop JA: Retinoblastoma, melanoma and the atypical mole syndrome. Br J Dermatol 132: 134-138, 1995

    Google Scholar 

  119. Moll AC, Imhof SM, Bouter LM, Tan KE: Second primary tumors in patients with retinoblastoma. A review of the literature (Review) (33 refs.). Ophthalmic Genet 18: 27-34, 1997

    Google Scholar 

  120. Kowalik TF, DeGregori J, Schwarz JK, Nevins JR: E2F1 overexpression in quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis. J Virol 69: 2491-2500, 1995

    Google Scholar 

  121. Phillips AC, Bates S, Ryan KM, Helin K, Vousden KH: Induction of DNA synthesis and apoptosis are separable functions of E2F-1. Genes Dev 11: 1853-1863, 1997

    Google Scholar 

  122. Holmberg C, Helin K, Sehested M, Karlstrom O: E2F-1-induced p53-independent apoptosis in transgenic mice. Oncogene 17: 143-155, 1998

    Google Scholar 

  123. DeGregori J, Leone G, Miron A, Jakoi L, Nevins JR: Distinct roles for E2F proteins in cell growth control and apoptosis. Proc Natl Acad Sci USA 94: 7245-7250, 1997

    Google Scholar 

  124. Shan B, Farmer AA, Lee WH: The molecular basis of E2F-1/DP-1-induced S-phase entry and apoptosis. Cell Growth Differ 7: 689-697, 1996

    Google Scholar 

  125. Ohta Y, Kijima H, Kashanisabet M, Scanlon KJ: Suppression of the malignant phenotype of melanoma cells by anti-oncogene ribozymes. J Invest Dermatol 106: 275-280, 1996

    Google Scholar 

  126. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753-756, 1994

    Google Scholar 

  127. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RSr, Johnson BE, Skolnick MH: A cellcycle regulator potentially involved in genesis of many tumor types (see comments). Science 264: 436-440, 1994

    Google Scholar 

  128. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J et al.: Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8: 23-26, 1994

    Google Scholar 

  129. Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmannhieb E, Deplaen E, Hankeln T, Zumbuschenfelde KHM, Beach D: A p 16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269: 1281-1284, 1995

    Google Scholar 

  130. Halaban R, Cheng E, Zhang Y, Mandigo CE, Miglarese MR: Release of cell cycle constraints in mouse melanocytes by overexpressed mutant E2F1E132, but not by deletion of p16INK4A or p21WAF1/CIP1. Oncogene 16: 2489-2501, 1998

    Google Scholar 

  131. Castellano M, Gabrielli BG, Hussussian CJ, Dracopoli NC, Hayward NK: Restoration of CDKN2A into melanoma cells induces morphologic changes and reduction in growth rate but not anchorage-independent growth reversal. J Invest Dermatol 109: 61-68, 1997

    Google Scholar 

  132. Florenes VA, Lu C, Bhattacharya N, Rak J, Sheehan C, Slingerland JM, Kerbel RS: Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma. Oncogene 18: 1023-1032, 1999

    Google Scholar 

  133. Jiang HP, Lin JJ, Su ZZ, Goldstein NI, Fisher PB: Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene 11: 2477-2486, 1995

    Google Scholar 

  134. Trotter MJ, Tang L, Tron VA: Overexpression of the cyclin-dependent kinase inhibitor p21WAF1/CIP1 in human cutaneous malignant melanoma. J Cutan Pathol 24: 265-271, 1997

    Google Scholar 

  135. Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, Vogelstein B, Jacks T: p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage Genes Dev 9: 935-944, 1995

    Google Scholar 

  136. Mantel C, Luo Z, Canfield J, Braun S, Deng C, Broxmeyer HE: Involvement of p21cip-1 and p27kip-1 in the molecular mechanisms of steel factor-induced proliferative synergy in vitro and of p21cip-1 in the maintenance of stem/progenitor cells in vivo. Blood 88: 3710-3719, 1996

    Google Scholar 

  137. Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, Sherr CJ: The p21Cip1 and p27Kip1 CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 18: 1571-1583, 1999

    Google Scholar 

  138. Halaban R, Funasaka Y, Lee P, Rubin J, Ron D, Birnbaum D: Fibroblast growth factors in normal and malignant melanocytes. Ann NY Acad Sci 638: 232-243, 1991

    Google Scholar 

  139. Gaudray P, Szepetowski P, Escot C, Birnbaum D, Theillet C: DNA amplification at 11q13 in human cancer: from complexity to perplexity (Review). Mutat Res 276: 317-328, 1992

    Google Scholar 

  140. Sherr CJ: D-type cyclins (Review). Trends Biochem Sci 20: 187-190, 1995

    Google Scholar 

  141. Bartkova J, Lukas J, Strauss M, Bartek J: Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene 10: 775-778, 1995

    Google Scholar 

  142. Hall M, Peters G: Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer (Review) (219 refs.). Adv Cancer Res 68: 67-108, 1996

    Google Scholar 

  143. Lukas J, Herzinger T, Hansen K, Moroni MC, Resnitzky D, Helin K, Reed SI, Bartek J: Cyclin E-induced S phase without activation of the pRb/E2F pathway. Genes Dev 11: 1479-1492, 1997

    Google Scholar 

  144. Gray-Bablin J, Zalvide J, Fox MP, Knickerbocker CJ, DeCaprio JA, Keyomarsi K: Cyclin E, a redundant cyclin in breast cancer. Proc Natl Acad Sci USA 93: 15215-15220, 1996

    Google Scholar 

  145. Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ: Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 56: 2973-2978, 1996

    Google Scholar 

  146. Patel V, Senderowicz AM, Pinto D, Jr, Igishi T, Raffeld M, Quintanilla-Martinez L, Ensley JF, Sausville EA, Gutkind JS: Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Invest 102: 1674-1681, 1998

    Google Scholar 

  147. Schrump DS, Matthews W, Chen GA, Mixon A, Altorki NK: Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells. Clin Cancer Res 4: 2885-2890, 1998

    Google Scholar 

  148. Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L, Hill K, Steinberg SM, Figg WD, Tompkins A, Arbuck SG, Sausville EA: Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 16: 2986-2999, 1998

    Google Scholar 

  149. Halaban R, Cheng C, Smicun Y, Germino J: Deregulated E2F transcriptional activity in autonomously growing melanoma cells. J Exp Med, in press, 2000

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Yale University School of Medicine, New Haven, CT, USA

    Ruth Halaban

Authors
  1. Ruth Halaban
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Halaban, R. Melanoma Cell Autonomous Growth: The Rb/E2F Pathway. Cancer Metastasis Rev 18, 333–343 (1999). https://doi.org/10.1023/A:1006396104073

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006396104073

Search

Navigation